Women’s health & diagnostics veteran to lead company’s growth

Decades old habits influenced by commercials and direct to consumer marketing by J&J have contributed to increased exposure.

GynTect, a molecular diagnostic test developed by oncgnostics, allows reliable diagnostics of cervical cancer and the corresponding precancerous stages. The test has been revised now, offering an extension of its application, as compared to the first version. This extended version of GynTect is now available for use in laboratories. Moreover, oncgnostics has launched a crowd-investing campaign that offers small investors the opportunity to participate in the success of the company.

Women across the country are being warned that using talcum powder as part of their feminine hygiene routine may increase their risk of ovarian cancer, and in an editorial published last month in Time magazine, an associate professor of African and African Diaspora Studies at the University of Texas suggested that African American women may be at a greater risk than other women, due to strategic marketing by companies that sell talc based products.

Incontinence Underwear Company Aims to Raise Awareness for Cervical Health Issues

DP Medical Systems Ltd has secured a deal with Cervical Screening Wales to provide its pioneering image capture system for gynaecological examinations - MediScan - to hospitals across the country.

Charles Irion as a Director of The 3000 Club will be Assisting Doctors and Nurses during a Cervical Cancer Treatment and Education Mission

oncgnostics develops, based on proprietary epigenetic biomarkers molecular tests for reliable cancer diagnostics. This test allows reliable diagnostics of cervical cancer and its pre-stages. Now oncgnostics has raised a seven-digit Euro amount in a Series A financing round.